UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of December, 2023
Commission
File Number 001-41749
PIXIE
DUST TECHNOLOGIES, INC.
(Translation
of registrant’s name into English)
Pixie
Dust Technologies, Inc.
2-2-1
Yaesu, Chuo-ku
Tokyo, 104-0028, Japan
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form
20-F ☐ Form 40-F
INFORMATION
CONTAINED IN THIS FORM 6-K REPORT
Issuance
of Press Release
On
December 14, 2023, Pixie Dust Technologies, Inc. (the “Company”) issued a press release announcing that a Company-sponsored experiment on the Company’s SonoRepro™ product was recently conducted by Dr. Akinobu Miyata, Director of Miyata Medical Clinic,
in collaboration with the Japan Clinical Trial Association (JACTA).
The
press release furnished in this report as Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to
be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, as amended,
except to the extent specifically provided in such a filing.
EXHIBIT
INDEX
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
Date: December 14, 2023 |
Pixie Dust Technologies, Inc. |
|
|
|
|
By: |
/s/ Yoichi Ochiai |
|
|
Name: |
Yoichi Ochiai |
|
|
Title: |
Chief Executive Officer |
Exhibit 99.1
SonoRepro™
by Pixie Dust Technologies, Inc.
Featured in Medical
Practice and New Drugs 2023 Study
New
Study Showcases Efficacy of SonoRepro™
New York, New York and Tokyo, Japan,
December 14, 2023 – Pixie Dust Technologies, Inc. (Nasdaq: PXDT) (the “Company”),
a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology,
today announced that a Company-sponsored experiment on the Company’s SonoRepro™ product was recently conducted by Dr. Akinobu
Miyata, Director of Miyata Medical Clinic, in collaboration with the Japan Clinical Trial Association (JACTA).
The study, aimed at determining the effects
on the scalp and hair when using SonoRepro™ with scalp lotion for 12 weeks, consisted of adult men and women under 49 years old
who were concerned about thinning hair. The goal of the study was to utilize a test group and control group to determine whether results
were significant.
As part of the study, scalp lotion was
applied to the top of the head, and ultrasonic waves were irradiated to the scalp by SonoRepro™ to cover the center of the application
area. SonoRepro™’s non-contact vibrotactile stimulation is a technology that irritates the skin without physically touching
it, using ultrasonic waves transmitted through the air.
In comparing the results of the test group
with the control group, the outcome revealed that the study participants who received treatment via SonoRepro™ showed a meaningful
improvement in hair diameter, head condition, and scalp water content.
“The recent study evidenced the efficacy
of our technology across both genders and different age groups,” said Pixie Dust Technologies, Inc. CRO Takayuki Hoshi. “Moving
forward, we intend to further explore the potential of our wave control technology in the healthcare sector.”
Forward-Looking Statements
Certain statements
contained in this press release are “forward-looking statements” made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the Company’s current expectations or beliefs
concerning future events and actual events may differ materially from current expectations. Any such forward-looking statements are subject
to various risks and uncertainties, including the strength of the economy, changes to the market for securities, political or financial
instability and other factors which are set forth in the Company’s Annual Report on Form 20-F for the year ended April 30, 2023
(File No. 001-41749) filed with the SEC, and in all filings with the SEC made by the Company
subsequent to the filing thereof. The Company does not undertake to publicly update or revise its forward-looking statements, whether
as a result of new information, future events or otherwise.
About Pixie Dust Technologies, Inc.
Pixie Dust Technologies, Inc. is a Japanese
technology company focused on commercializing innovative products and materials utilizing proprietary wave technology. The Company is
currently focusing on two areas of product development: (1) “Personal Care & Diversity”, where wave control technology
is applied to mechanobiology and intervention/assistance in vision, hearing, and touch, and (2) “Workspace & Digital Transformation,”
where metamaterials (technology that creates properties through structure rather than material) and solutions to commercial design problems,
such as in offices or construction sites, are applied.
Pixie Dust Technologies Investor Relations
Contact:
Email: PXDT_IR@pixiedusttech.com
Gateway Group, Inc.
John Yi and Luke Johnson
Email: pixie@gateway-grp.com
Pixie Dust Technologies (NASDAQ:PXDT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pixie Dust Technologies (NASDAQ:PXDT)
Historical Stock Chart
From Sep 2023 to Sep 2024